Get the Stockscreener App
141.69
2.27%
-3.29
After Hours:
142.50
0.81
+0.57%
Celcuity Inc stock is traded at $141.69, with a volume of 1.42M.
It is down -2.27% in the last 24 hours and up +25.80% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$144.98
Open:
$145.215
24h Volume:
1.42M
Relative Volume:
1.79
Market Cap:
$6.85B
Revenue:
-
Net Income/Loss:
$-177.04M
P/E Ratio:
-37.42
EPS:
-3.7867
Net Cash Flow:
$-153.53M
1W Performance:
+18.01%
1M Performance:
+25.80%
6M Performance:
+89.96%
1Y Performance:
+1,206%
1-Day Range:
$139.31
$147.33
1-Week Range:
$116.50
$151.02
52-Week Range:
$9.51
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
141.69 | 7.01B | 0 | -177.04M | -153.53M | -3.7867 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge? - Yahoo Finance
ASCO 2026 preview – Celcuity gets a mutant coup | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer - Clinical Trials Arena
Celcuity’s gedatolisib beats Novartis drug in Phase III test - The Pharma Letter
CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal - timothysykes.com
CELC Stock Jumps As VIKTORIA-1 Data Fuel FDA Push - StocksToTrade
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes - TechStock²
CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street - timothysykes.com
Celcuity strengthens case for ASCO-spotlighted breast cancer drug - BioPharma Dive
Celcuity CELC Soars On Strong Phase 3 Cancer Data - StocksToTrade
Celcuity rises on gedatolisib on top-line data in breast cancer - BioWorld News
Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib - Quiver Quantitative
Wall Street believes Celcuity could become an acquisition target – why this analyst raised their price target by a whopping 76% - MSN
CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone - timothysykes.com
Celcuity upgraded by H.C. Wainwright with a new price target - Quantisnow
Citizens raises Celcuity stock price target on Phase 3 trial win By Investing.com - Investing.com South Africa
Citizens raises Celcuity stock price target on Phase 3 trial win - Investing.com
Celcuity’s breast cancer win; Odyssey plans $205M IPO - Endpoints News
Needham raises Celcuity stock price target to $157 on trial data - Investing.com UK
Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data - International Business Times Australia
Needham raises Celcuity stock price target to $157 on trial data By Investing.com - Investing.com South Africa
Guggenheim raises Celcuity stock price target on trial success By Investing.com - Investing.com Canada
Guggenheim raises Celcuity stock price target on trial success - Investing.com
Stifel raises Celcuity stock price target on trial data strength By Investing.com - Investing.com Australia
Celcuity upgraded to Buy from Neutral at H.C. Wainwright - TipRanks
Stifel raises Celcuity stock price target on trial data strength - Investing.com
Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results - marketscreener.com
Celcuity price target raised to $157 from $122 at Needham - TipRanks
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76% - Stocktwits
Why Is Celcuity Stock Rallying Today? - Benzinga
As FDA decision nears, Celcuity posts win in PIK3CA-mutant breast cancer - FirstWord Pharma
Why Celcuity’s Hot Cancer Drug Stock Is Sinking - TipRanks
CELC stock jumps after hours on positive breast cancer trial data - MSN
Celcuity Stock Surges on Breakthrough Trial Results - TipRanks
Celcuity’s Gedatolisib Achieves Phase 3 Success in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer, Meeting Primary Endpoint in VIKTORIA-1 Trial 1 - Minichart
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Jennison Associates LLC Purchases Shares of 229,704 Celcuity, Inc. $CELC - MarketBeat
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Celcuity Reports Positive Phase 3 Results for Gedatolisib - TipRanks
Why Celcuity Shares Are Dropping After Big Trial Win - TipRanks
Celcuity reports positive phase 3 trial results for gedatolisib By Investing.com - Investing.com Nigeria
Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort. - Bitget
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort - The Manila Times
Celcuity reports positive phase 3 trial results for gedatolisib - Investing.com
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful ... - Caledonian Record
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary - GlobeNewswire
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Celcuity (CELC) Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt FinancingHas The Bull Case Changed? - simplywall.st
CELC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):